Effect of two different combinations of antiretrovirals (AZT+ddI and AZT+3TC) on cytokine production and apoptosis in asymptomatic HIV infection

Stefania Piconi, Daria Trabattoni, Maria Luisa Fusi, Francesco Milazzo, Lynn P. Dix, Giuliano Rizzardini, Fulvia Colombo, Dorothy Bray, Mario Clerici

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Nineteen HIV-seropositive antiretroviral therapy-naive and asymptomatic individuals (200-500 CD4/μl) were enrolled in a prospective study aimed at analyzing the immunologic and virologic effects of two different combinations of nucleoside reverse transcriptase inhibitors (AZT+ddI and AZT+3TC), and randomly assigned to one of the treatment group. Immunologic (CD4 and CD8 counts, mitogen-stimulated cytokine production, unstimulated and mitogen-stimulated apoptosis) and virologic (HIV viral load) determinations were performed pre-therapy and 15, 30, 90, 200 and 360 days after initiation of therapy. Results showed that the two combinations had comparable effects on increasing CD4 counts and the CD4/CD8 ratio and in reducing HIV viral load. In contrast, AZT+3TC was more efficient in improving interleukin-2 (IL-2) and interferon gamma (IFNγ) production as well as the type 1/type 2 cytokine ratio and in down modulating the susceptibility of peripheral blood mononuclear cells to in vitro mitogen-stimulated apoptotic cell death. These data suggest that the combination of AZT+3TC has a stronger effect on potentially beneficial immune parameters (IL-2 production; reduction of apoptosis) than the one between AZT+ddI. The combination of AZT+3TC could be more advantageous in the therapy of HIV infection even when used in association with a protease inhibitor. Copyright (C) 2000 Elsevier Science B.V.

Original languageEnglish
Pages (from-to)171-179
Number of pages9
JournalAntiviral Research
Volume46
Issue number3
DOIs
Publication statusPublished - Jun 1 2000

Fingerprint

Asymptomatic Infections
Lamivudine
HIV Infections
Mitogens
Apoptosis
Cytokines
HIV
CD4 Lymphocyte Count
Viral Load
Interleukin-2
CD4-CD8 Ratio
Reverse Transcriptase Inhibitors
Therapeutics
Protease Inhibitors
Nucleosides
Interferon-gamma
Blood Cells
Cell Death
Prospective Studies

Keywords

  • Antiviral therapy
  • Apoptosis
  • Cytokine
  • HIV infection
  • Immunology

ASJC Scopus subject areas

  • Virology
  • Pharmacology

Cite this

Effect of two different combinations of antiretrovirals (AZT+ddI and AZT+3TC) on cytokine production and apoptosis in asymptomatic HIV infection. / Piconi, Stefania; Trabattoni, Daria; Fusi, Maria Luisa; Milazzo, Francesco; Dix, Lynn P.; Rizzardini, Giuliano; Colombo, Fulvia; Bray, Dorothy; Clerici, Mario.

In: Antiviral Research, Vol. 46, No. 3, 01.06.2000, p. 171-179.

Research output: Contribution to journalArticle

Piconi, Stefania ; Trabattoni, Daria ; Fusi, Maria Luisa ; Milazzo, Francesco ; Dix, Lynn P. ; Rizzardini, Giuliano ; Colombo, Fulvia ; Bray, Dorothy ; Clerici, Mario. / Effect of two different combinations of antiretrovirals (AZT+ddI and AZT+3TC) on cytokine production and apoptosis in asymptomatic HIV infection. In: Antiviral Research. 2000 ; Vol. 46, No. 3. pp. 171-179.
@article{404f0b6dd7ec4274916e3fbdbc2dfd31,
title = "Effect of two different combinations of antiretrovirals (AZT+ddI and AZT+3TC) on cytokine production and apoptosis in asymptomatic HIV infection",
abstract = "Nineteen HIV-seropositive antiretroviral therapy-naive and asymptomatic individuals (200-500 CD4/μl) were enrolled in a prospective study aimed at analyzing the immunologic and virologic effects of two different combinations of nucleoside reverse transcriptase inhibitors (AZT+ddI and AZT+3TC), and randomly assigned to one of the treatment group. Immunologic (CD4 and CD8 counts, mitogen-stimulated cytokine production, unstimulated and mitogen-stimulated apoptosis) and virologic (HIV viral load) determinations were performed pre-therapy and 15, 30, 90, 200 and 360 days after initiation of therapy. Results showed that the two combinations had comparable effects on increasing CD4 counts and the CD4/CD8 ratio and in reducing HIV viral load. In contrast, AZT+3TC was more efficient in improving interleukin-2 (IL-2) and interferon gamma (IFNγ) production as well as the type 1/type 2 cytokine ratio and in down modulating the susceptibility of peripheral blood mononuclear cells to in vitro mitogen-stimulated apoptotic cell death. These data suggest that the combination of AZT+3TC has a stronger effect on potentially beneficial immune parameters (IL-2 production; reduction of apoptosis) than the one between AZT+ddI. The combination of AZT+3TC could be more advantageous in the therapy of HIV infection even when used in association with a protease inhibitor. Copyright (C) 2000 Elsevier Science B.V.",
keywords = "Antiviral therapy, Apoptosis, Cytokine, HIV infection, Immunology",
author = "Stefania Piconi and Daria Trabattoni and Fusi, {Maria Luisa} and Francesco Milazzo and Dix, {Lynn P.} and Giuliano Rizzardini and Fulvia Colombo and Dorothy Bray and Mario Clerici",
year = "2000",
month = "6",
day = "1",
doi = "10.1016/S0166-3542(00)00076-0",
language = "English",
volume = "46",
pages = "171--179",
journal = "Antiviral Research",
issn = "0166-3542",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Effect of two different combinations of antiretrovirals (AZT+ddI and AZT+3TC) on cytokine production and apoptosis in asymptomatic HIV infection

AU - Piconi, Stefania

AU - Trabattoni, Daria

AU - Fusi, Maria Luisa

AU - Milazzo, Francesco

AU - Dix, Lynn P.

AU - Rizzardini, Giuliano

AU - Colombo, Fulvia

AU - Bray, Dorothy

AU - Clerici, Mario

PY - 2000/6/1

Y1 - 2000/6/1

N2 - Nineteen HIV-seropositive antiretroviral therapy-naive and asymptomatic individuals (200-500 CD4/μl) were enrolled in a prospective study aimed at analyzing the immunologic and virologic effects of two different combinations of nucleoside reverse transcriptase inhibitors (AZT+ddI and AZT+3TC), and randomly assigned to one of the treatment group. Immunologic (CD4 and CD8 counts, mitogen-stimulated cytokine production, unstimulated and mitogen-stimulated apoptosis) and virologic (HIV viral load) determinations were performed pre-therapy and 15, 30, 90, 200 and 360 days after initiation of therapy. Results showed that the two combinations had comparable effects on increasing CD4 counts and the CD4/CD8 ratio and in reducing HIV viral load. In contrast, AZT+3TC was more efficient in improving interleukin-2 (IL-2) and interferon gamma (IFNγ) production as well as the type 1/type 2 cytokine ratio and in down modulating the susceptibility of peripheral blood mononuclear cells to in vitro mitogen-stimulated apoptotic cell death. These data suggest that the combination of AZT+3TC has a stronger effect on potentially beneficial immune parameters (IL-2 production; reduction of apoptosis) than the one between AZT+ddI. The combination of AZT+3TC could be more advantageous in the therapy of HIV infection even when used in association with a protease inhibitor. Copyright (C) 2000 Elsevier Science B.V.

AB - Nineteen HIV-seropositive antiretroviral therapy-naive and asymptomatic individuals (200-500 CD4/μl) were enrolled in a prospective study aimed at analyzing the immunologic and virologic effects of two different combinations of nucleoside reverse transcriptase inhibitors (AZT+ddI and AZT+3TC), and randomly assigned to one of the treatment group. Immunologic (CD4 and CD8 counts, mitogen-stimulated cytokine production, unstimulated and mitogen-stimulated apoptosis) and virologic (HIV viral load) determinations were performed pre-therapy and 15, 30, 90, 200 and 360 days after initiation of therapy. Results showed that the two combinations had comparable effects on increasing CD4 counts and the CD4/CD8 ratio and in reducing HIV viral load. In contrast, AZT+3TC was more efficient in improving interleukin-2 (IL-2) and interferon gamma (IFNγ) production as well as the type 1/type 2 cytokine ratio and in down modulating the susceptibility of peripheral blood mononuclear cells to in vitro mitogen-stimulated apoptotic cell death. These data suggest that the combination of AZT+3TC has a stronger effect on potentially beneficial immune parameters (IL-2 production; reduction of apoptosis) than the one between AZT+ddI. The combination of AZT+3TC could be more advantageous in the therapy of HIV infection even when used in association with a protease inhibitor. Copyright (C) 2000 Elsevier Science B.V.

KW - Antiviral therapy

KW - Apoptosis

KW - Cytokine

KW - HIV infection

KW - Immunology

UR - http://www.scopus.com/inward/record.url?scp=0034212692&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034212692&partnerID=8YFLogxK

U2 - 10.1016/S0166-3542(00)00076-0

DO - 10.1016/S0166-3542(00)00076-0

M3 - Article

C2 - 10867155

AN - SCOPUS:0034212692

VL - 46

SP - 171

EP - 179

JO - Antiviral Research

JF - Antiviral Research

SN - 0166-3542

IS - 3

ER -